Susquehanna Fundamental Investments LLC Reduces Position in West Pharmaceutical Services, Inc. (NYSE:WST)

Susquehanna Fundamental Investments LLC decreased its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 64.8% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 6,454 shares of the medical instruments supplier’s stock after selling 11,899 shares during the period. Susquehanna Fundamental Investments LLC’s holdings in West Pharmaceutical Services were worth $2,126,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Fidelis Capital Partners LLC purchased a new position in West Pharmaceutical Services during the first quarter worth $27,000. Crewe Advisors LLC grew its position in shares of West Pharmaceutical Services by 322.7% in the second quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 71 shares during the period. Quarry LP grew its position in shares of West Pharmaceutical Services by 155.3% in the fourth quarter. Quarry LP now owns 97 shares of the medical instruments supplier’s stock valued at $34,000 after purchasing an additional 59 shares during the period. Hazlett Burt & Watson Inc. purchased a new stake in shares of West Pharmaceutical Services in the first quarter valued at $40,000. Finally, Northwest Investment Counselors LLC purchased a new stake in shares of West Pharmaceutical Services in the first quarter valued at $40,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.

Insider Activity at West Pharmaceutical Services

In related news, VP Charles Witherspoon sold 1,029 shares of West Pharmaceutical Services stock in a transaction on Monday, August 19th. The stock was sold at an average price of $300.00, for a total value of $308,700.00. Following the transaction, the vice president now owns 1,478 shares in the company, valued at $443,400. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.53% of the stock is owned by insiders.

West Pharmaceutical Services Price Performance

Shares of NYSE:WST opened at $300.16 on Tuesday. The company has a market cap of $21.77 billion, a P/E ratio of 39.60, a P/E/G ratio of 11.09 and a beta of 1.01. The company has a quick ratio of 1.68, a current ratio of 2.34 and a debt-to-equity ratio of 0.03. West Pharmaceutical Services, Inc. has a 52 week low of $265.00 and a 52 week high of $413.70. The business has a fifty day simple moving average of $301.57 and a 200-day simple moving average of $334.35.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, July 25th. The medical instruments supplier reported $1.52 EPS for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.22). The business had revenue of $702.10 million during the quarter, compared to analysts’ expectations of $729.36 million. West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. West Pharmaceutical Services’s revenue for the quarter was down 6.9% on a year-over-year basis. During the same period in the prior year, the firm earned $2.11 EPS. Equities research analysts forecast that West Pharmaceutical Services, Inc. will post 6.42 EPS for the current year.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.